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In a recent issue of Arthritis Research and Th  erapy, 
Higashi-Kuwata and colleagues elegantly showed evi-
dence that macrophages/monocytes with a proﬁ  brotic 
proﬁ  le may be involved in the pathogenesis of systemic 
sclerosis (SSc) [1]. Early studies of the histopathology of 
SSc showed that macrophages are found in dermal 
perivascular and interstitial inﬁ  ltrates,  particularly 
promi  nent in perivascular inﬁ  ltrates of early diﬀ  use SSc 
skin [2], and in SSc-associated interstitial lung disease 
[3]. Tissue macrophages show markers of activation in 
SSc skin expressing increased HLA-DR and platelet-
derived growth factor type B receptor [4] and MCP-1/
CCL2 [5], and in bronchoalveolar lavage ﬂ  uid secreting 
increased IL-8 [6] and endothelin-1 [7].
More recent studies have shown that SSc monocytes 
express allograft inhibitory factor-1 [8]. Data from our 
group indicate that allograft inhibitory factor-1 expres-
sion in circulating monocytes is part of an interferon-
responsive gene expression signature in SSc patients [9] 
(RBC and RL, unpublished observations). Strikingly, in 
patients showing upregulated interferon-responsive genes, 
all CD14+ monocytes expressed increased sialoadhesin, 
suggesting that interferon activates the entire monocyte 
population. In addition, several genes associated with 
monocyte/macrophage recruitment and diﬀ  erentiation 
were overexpressed in recent microarray analyses of SSc 
peripheral blood mononuclear cells, compared with 
healthy controls [10].
Macrophages exposed to IFNγ undergo classical 
activation, referred to as M1, and have powerful anti-
microbial activity. In contrast, IL-4 and IL-13 (Th  2  cyto-
kines) switch macrophages to a M2 phenotype, enhanc-
ing endocytosis and pinocytosis, repressing proinﬂ  am-
ma  tory cytokines and stimulating tissue remodeling [11]. 
Although the M1/M2 paradigm serves as a useful 
extension of Th  1/Th   2-mediated immune responses, it is 
inadequate for completely understanding monocyte res-
ponses to cytokines and their diﬀ  erentiation into macro-
phages, because many other mediators impact on this 
process, including glucocorticoids, toll-like receptor-4 
ligands and IL-10 [11]. Although more complex models 
of monocyte maturation into macrophages have been 
developed – such as M2a (IL-4/IL-13 activated), M2b 
(immune complex or toll-like receptor activated) and 
M2c (IL-10 or glucocorticoid activated) [12] – it may be 
more appropriate to consider monocytes as responding 
to a cytokine/innate immune mediator language. Perhaps 
most relevant in autoimmune disease is the role of type I 
interferons, as they are also able to activate monocytes – 
stimulating dendritic cell diﬀ  erentiation in vitro and, in a 
model of chronic inﬂ  ammation, blocking maturation of 
Ly6Chi monocytes into Ly6Clo resident monocytes 
typically recruited to non-inﬂ  amed tissues [13].
In this context, Higashi-Kuwata and colleagues found 
that CD68, a pan-macrophage indicator, and two markers 
of macrophage activation, CD163 and CD204, were 
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© 2010 BioMed Central Ltdincreased in SSc patients. Speciﬁ  cally in the skin, these 
activation markers were highly expressed in perivascular 
regions and between thickened collagen bundles. As M2 
macrophages are important sources of many cytokines, 
such as transforming growth factor beta, they may be 
responsible for the ﬁ   brotic phenotype of SSc patients 
[11]. Although these markers are suggestive of alternative 
macrophage activation, CD163 can also be stimulated by 
IL-10 [14] and the M1 versus M2 phenotype asso  ciation 
with CD204 remains unclear [15]. Of note, however, 
CD204-deleted mice fail to develop silica-induced 
ﬁ   brosis consistent with a key role for this scavenger 
receptor in proﬁ  brotic disease [16]. Further investigation 
into the role of these surface markers and IL-4/IL-13 
monocyte/macrophage activation in SSc is therefore 
clearly needed.
Th  e authors also analyzed CD14+ populations in the 
blood of these patients. Interestingly, they found a minor 
CD14hi population of circulating monocytes in SSc 
patients. Th   ese results are notable because CD14++CD16–/
CX3CR1lo versus CD14+CD16+/CX3CR1hi in humans (and 
Ly-6hi/Gr-1hi versus Ly-6lo/Gr-1lo in the mouse) have been 
described to represent distinct monocyte subpopulations: 
the former (CD14++CD16–) turning into tissue 
macrophages and possibly dendritic cells or matur  ing into 
CD14+CD16+, the major circulating monocyte population; 
the latter (CD14+CD16+) turning into resi  dent tissue 
monocyte/macrophages [17,18]. Th  e CD14hi monocyte 
population described by Higashi-Kuwata and colleagues 
thus might be normally short-lived CD14++CD16– 
monocytes destined for inﬂ  ammatory sites. Based on the 
recent observations in mice [13], type I interferon might 
play a role in this process by blocking maturation of 
CD14++CD16– into CD14+CD16+ mono  cytes, and 
stimulating CCR2 expression and recruitment into in-
ﬂ  amed tissues. Th   is hypothesis contrasts with the increased 
CX3CR1+ cells reported in SSc previously [19], however, as 
CX3CR1+ is a marker for CD14+CD16+ cells and is thought 
responsible for recruiting these cells as resident tissue 
macrophages. Both, ie. CD14+CD16+CX3CR1+ and 
CD14++CD16–CXCR1– cells probably  represent distinct 
mono  cyte populations, and the resolution of this 
dilemma is likely to occur through understanding better 
the underlying cytokine/innate immune stimuli aﬀ  ecting 
SSc monocytes.
Higashi-Kuwata and colleagues further reported that 
the CD14hi (CD14bright or CD14++) population in SSc 
patients expresses higher levels of CD163 and CD204. 
Th  e expression of CD163 was greater in SSc patients, 
whereas CD204 did not distinguish SSc from the healthy 
controls. In order to further deﬁ  ne the CD14hi popu-
lation, the authors performed triple staining – conﬁ  rming 
that a minor CD14hiCD163+CD204+ population is 
increased in SSc patients.
Together these results suggest that SSc peripheral 
blood mononuclear cells develop an anti-inﬂ  ammatory 
and proﬁ  brotic M2 phenotype. Further studies will be 
needed to understand the signals causing these changes 
and whether they contribute to vascular injury and 
ﬁ  brosis.
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